



**Thursday, May 7th 2026**  
**ANU - Museum of the Jewish People, Tel Aviv**

|                    |  |
|--------------------|--|
| <b>08:00-09:00</b> | <b>Registration, Gathering, &amp; Exhibition</b>   |
| <b>09:00-09:30</b> | <p><b>Opening Remarks &amp; Greetings</b><br/> <b>Hagop Kantarjian, MD</b>, Chair of the Department of Leukemia, University of Texas MD Anderson Cancer Center, USA<br/> <b>Eytan Wirtheim, MD, MHA</b>, CEO Clalit Health Services, Israel<br/> <b>Erez Barenboim, MD</b>, CEO - Beilinson &amp; Hasharon Hospitals – Rabin Medical Center, Clalit Health Services, Israel<br/> <b>Karen Avraham, PhD</b>, Dean of the Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Israel<br/> <b>Nati Horowitz, MD</b>, Chairman, Israel Society of Hematology and Blood Transfusions, Israel<br/> <b>Gal Markel, MD</b>, Head, Davidoff Cancer Center, Rabin Medical Center, Israel<br/> <b>Pia Raanani, MD</b>, Head, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Israel</p> |
| <b>09:30-11:10</b> | <p><b>Session 1 - Acute Myeloid Leukemia (AML)</b><br/> <b>Chairpersons: Ofir Wolach, MD   Yakir Moshe, MD</b></p>   |
| 09:30-09:50        | <p><b>Managing Differentiation Syndrome in 2026: Steps Beyond Steroids</b><br/> <b>Dr. Eytan M. Stein, MD</b>, Memorial Sloan Kettering Cancer Center, NY, USA</p>   |
| 09:50-10:05        | <p><b>Triplet Strategies for AML</b><br/> <b>Courtney DiNardo, MD</b>, University of Texas MD Anderson Cancer Center, Houston, USA</p>   |
| 10:05-10:25        | <p><b>TBC</b><br/> <b>Stéphane de Botton, MD</b>, Institut Gustave Roussy, Villejuif (IGR), France</p>   |
| 10:25-10:40        | <p><b>TBC</b><br/> <b>Gail Roboz, MD</b>, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA</p>  |
| 10:40-11:00        | <p><b>2026 AML Induction Therapy: What Does it Mean?</b><br/> <b>Richard Stone, MD</b>, Dana Farber Cancer Institute, Boston, USA</p>  |
| 11:00-11:10        | <p><b>AML Panel Discussion</b></p>   |
| <b>11:10-11:30</b> | <b>Coffee Break &amp; Exhibition</b>   |
| <b>11:30-12:35</b> | <p><b>Session 2: Acute Lymphoblastic Leukemia (ALL)</b><br/> <b>Chairpersons: Irina Amitai, MD   Tzila Zuckerman, MD</b></p>   |
| 11:30-11:45        | <p><b>Research and Progress in B-Cell ALL at MD Anderson 2026</b><br/> <b>Hagop Kantarjian, MD</b>, University of Texas MD Anderson Cancer Center, Houston, USA</p>  |
| 11:45-12:00        | <p><b>Frontline Treatment for Ph+ ALL in 2026</b><br/> <b>Nicholas J Short, MD</b>, University of Texas MD Anderson Cancer Center, Houston, USA</p>  |
| 12:00-12:15        | <p><b>A Chemo-Free Approach Should be the New Standard for Adult Ph+ ALL. Evidence from the First Phase 3 Study</b><br/> <b>Robin Foà, MD</b>, Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy</p>   |

|                    |  |
|--------------------|--|
| <b>12:25-13:30</b> | <b>Session 3 - Chronic Lymphocytic Leukemia (CLL)</b><br><b>Chairpersons: Liron Hofstetter, MD   Yair Herishanu, MD</b>  |
| 12:25-12:45        | <b>Diagnosis and New Treatment Options in Richter Transformation</b><br><b>Dr. Barbara Eichhost, MD, University Hospital Cologne, Germany</b>  |
| 12:45-13:00        | <b>Frontline Treatment of Chronic Lymphocytic Leukemia in 2026</b><br><b>Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>                             |
| 13:00-13:20        | <b>TBC</b><br><b>Jan A. Burger, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>  |
| 13:20-13:30        | <b>CLL Panel Discussion</b>  |
| <b>13:30-14:20</b> | <b>Lunch &amp; Exhibition</b>  |
| <b>14:20-15:20</b> | <b>Session 4 - Myeloproliferative disorders (MPD)</b><br><b>Chairpersons: Adi Shacham - Abulafia, MD   Moshe Yeshurun, MD</b>  |
| 14:20-14:35        | <b>Myeloproliferative Neoplasms Latest Updates</b><br><b>Lucia Masarova, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>   |
| 14:35-14:55        | <b>Myelofibrosis and Cytopenia : Prognosis and Treatment</b><br><b>Mauricette Michallet, MD, Centre Léon Bérard, Lyon, France</b>  |
| 14:55-15:10        | <b>TBC</b><br><b>Jason Gotlib, MD, Hematology, Stanford Cancer Center Palo Alto, Palo Alto California</b>  |
| 15:10-15:20        | <b>MPD Panel Discussion</b>  |
| <b>15:20-16:15</b> | <b>Session 5 - Cellular Therapy</b><br><b>Chairpersons: Avichai Shimoni, MD   Moshe Gatt, MD</b>   |
| 15:20-15:35        | <b>Redefining Allogeneic Transplantation in the Era of Targeted and Cellular Therapies</b><br><b>Issa F. Khouri, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b> |
| 15:35-15:50        | <b>TBC</b><br><b>Koen van Besien, MD, PhD, UH Seidman Cancer Center, Cleveland, Ohio, USA</b>  |
| 15:50-16:05        | <b>Bispecific CARs Targeting CD19 and CD20 for Relapsed, Refractory DLBCL</b><br><b>Nirav N. Shah, MD, Medical College of Wisconsin, Milwaukee, Wisconsin, USA</b>                   |
| 16:05-16:15        | <b>Cellular Therapy Panel Discussion</b>   |
| <b>16:15-16:25</b> | <b>Closing Remarks</b>   |

**Friday, May 8th 2026**  
**Port Tower Hotel, Tel Aviv**

|                    |   |
|--------------------|---|
| <b>08:00-08:40</b> | <b>Gathering</b>  |
| <b>08:40-10:15</b> | <b>Session 6 – Chronic Myeloid Leukemia (CML)</b><br><b>Chairpersons: Pia Raanani, MD   Merav Leiba, MD</b>   |
| 08:40-09:00        | <b>Should Additional Genetic Abnormalities Drive 1st Line Treatment Choices?</b><br><b>Delphine Rea, MD, Hopital Saint-Louis, Paris, France</b>                 |
| 09:00-09:20        | <b>Mutations in CML: the Good, the Bad, the Ugly</b><br><b>Simona Soverini, PhD, Alma Mater Studiorum Universita di Bologna, Italy</b>                          |
| 09:20-09:40        | <b>TBC</b><br><b>Giuseppe Saglio, MD, University of Turin, Italy</b>  |
| 09:40-10:00        | <b>Optimizing Quality of Life in CML and CMPN</b><br><b>Philipp Le Coutre, MD, Charité - Universitätsmedizin Berlin, Germany</b>                                |
| 10:00-10:15        | <b>CML Panel Discussion</b>   |
| <b>10:15-10:35</b> | <b>Coffee Break</b>   |
| <b>10:35-11:50</b> | <b>Session 7 – Lymphomas and Plasma Cell Dyscrasias</b><br><b>Chairpersons: Juliana Vaxman, MD   Ronit Gurion, MD</b>   |
| 10:35-10:50        | <b>Next Steps for Hodgkin Lymphoma</b><br><b>Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA</b>  |
| 10:50-11:10        | <b>Amyloidosis when Dara Fails What's Next?</b><br><b>Morie Gertz, MD, Mayo Clinic Rochester Minnesota, USA</b>   |
| 11:10-11:25        | <b>TBC</b><br><b>Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA</b>   |
| 11:25-11:40        | <b>Relapse FL: CAR-T or Bispecific Antibody</b><br><b>Gilles Salles, MD, Memorial Sloan Kettering Cancer Center NY, USA</b>                                     |
| 11:40-11:50        | <b>Lymphomas and Plasma Cell Dyscrasias Panel Discussion</b>  |
| <b>11:50-12:50</b> | <b>Session 8 – MDS &amp; Bone marrow failure syndromes</b><br><b>Chairpersons: Renana Robinson, MD   Anat Gafter-Gvili, MD</b>                                  |
| 11:50-12:05        | <b>CMML Updates 2025 and Beyond</b><br><b>Eric Padron, MD, Moffitt Cancer Center, Tampa, Florida, USA</b>   |
| 12:05-12:20        | <b>New Paradigms in MDS</b><br><b>Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>                                  |
| 12:20-12:35        | <b>How Do We Change the Standard of Care for Higher Risk Myelodysplastic Syndromes</b><br><b>David A Sallman, MD, Moffitt Cancer Center Tampa, Florida, USA</b> |
| 12:35-12:50        | <b>Aplastic Anemia Management in 2026</b><br><b>Régis Peffault De La Tour, MD, PhD, Saint-Louis Hospital, Paris, France</b>                                     |
| 12:50-13:00        | <b>MDS &amp; Bone marrow failure syndromes Panel Discussion</b>   |
| <b>13:00-13:05</b> | <b>Closing Remarks</b>  |